- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03070860
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum (GOCAPXE)
Glucidic Metabolism, Ossification and Arterial Calcification During PseudoXanthoma Elasticum (PXE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pseudoxanthoma elasticum (PXE; OMIM 264800), is an autosomal recessive metabolic disorder characterized by the fragmentation and progressive calcification of elastic fibers(elastorrhexis) in connective tissue in the skin, Bruch's membrane of the retina and the vascular system. PXE is caused by mutations in the ABCC6 (ATP-binding cassette subfamily C member 6) gene, located on the short arm of chromosome 16, encoding a transmembrane ATP binding anion transporter normally expressed in the liver and the kidney. The pathophysiology of PXE, particularly the mechanism of ectopic mineralization, remains largely unknown. PXE is currently an intractable disease, associated with considerable morbidity and occasional mortality due to cardiovascular complications. The major symptoms of the disease are characterized by unaesthetic skin folds, central blindness and cardiovascular complication with an early and severe peripheral arterial disease (PAD) and complication at younger age than the normal population. Unfortunately, histological studies are limited by the availability of arterial tissue from patients but it has been showed calcium deposition in the media layer of the large (i.e. aorta, carotids and femoral) and medium sized vessels (i.e. radial and ankle arteries) (ref). However, the underlying pathophysiology for arterial calcification in PXE remains incompletely defined, and there are currently no effective medical treatments capable of altering its course.
No longitudinal study has been performed to explain the calcification process in PXE. As PXE is a systemic metabolic disease, low grade inflammation could be the trigger of a deregulated inflammation resolution process resulted in calcification. Thus, alternative techniques are therefore required to investigate the pathogenesis and progression of this condition.
Positron emission tomography (PET) combined with computed tomography (CT) is a noninvasive imaging technique that allows the identification and quantification of specific biochemical processes within small anatomic structures, such as vascular wall. Furthermore, 2 common PET tracers target calcification and inflammation, which are believed to play a key role in the development of the disease. 18F Flurodeoxyglucose (18F-FDG) is a glucose analogue that is taken up into cells by glucose transport proteins and enters the glycolytic metabolic pathway. After the initial hexokinase step, 18F-FDG-6-phosphate cannot be metabolized further and becomes trapped within cells that have high metabolic requirements, such as macrophages. PET imaging with the use of 18F-FDG has become an established means of quantifying vascular inflammation in both the aorta and carotid arteries, correlating with plaque macrophage burden and symptomatic status. 18F-Sodium fluoride (18FNaF) is an alternative PET tracer that is directly incorporated into exposed bone crystal (hydroxyapatite) via an exchange mechanism with hydroxyl groups. It is therefore thought to detect areas of novel calcification and regions of calcium remodeling and is used clinically for the detection of primary osteoblastic tumors and bone metastases. More recently, studies have described 18F-NaF uptake as a marker of calcification within atherosclerotic plaque. More recently, the calcifying process was examined in 4 PXE patients using 18NaF PET/CT showing in the femoral arteries, increased arterial wall 18NaF signal at levels similar to those for cortical bone. However, the mechanism responsible for the increased osteoblastic activity leading to arterial wall calcification in PXE remains unknown.
.
In this study, the investigators investigated 18F-NaF and 18F-FDG uptake in the arterial wall and skin of patients with PXE with 3 major aims: :
- Does low grade inflammation in vascular wall and skin exist in PXE patient and a specificity site might exist?
- Does low grade inflammation in vascular wall and skin quantified by 18F-FDG preceed the molecular calcification process quantified by 18F-NaF?
- Does low grade inflammation and bone turn over correlate conversely to calcium score?
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- PXE patient diagnosed according the international criteria
- Informed consent obtained
- Patient affiliated to Health care system
Exclusion criteria included inability or unwillingness to provide informed consent. Also, women of childbearing age not receiving contraception, pregnant women, nursing women, diabetic patients, patients with osteopenia, inflammatory or autoimmune systemic disease, high blood glucose concentrations (> 11 mmol/L) because of the competition between glucose and 18F-FDG for cellular entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PXE Patient
positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
|
Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department. PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vascular Inflammation
Time Frame: 90min post injection : 1 time
|
Measurement 18F-FDG TBRs of patients with PXE; and the comparison of 18F-NaF femoral arteries' TBRs with popliteal artery's TBRs of patients with PXE (at 30 min and 90min post injection).
|
90min post injection : 1 time
|
Molecular Calcification
Time Frame: 90min post injection : 1 time
|
Measurement 18F-NaF femoral arteries' TBRs with popliteal artery's TBRs of patients with PXE
|
90min post injection : 1 time
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Loukman OMARJEE, MD,MSc, University Hospital, Angers
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Skin Diseases
- Congenital Abnormalities
- Hematologic Diseases
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Hemostatic Disorders
- Skin Diseases, Genetic
- Skin Abnormalities
- Calcium Metabolism Disorders
- Pseudoxanthoma Elasticum
- Calcinosis
- Molecular Mechanisms of Pharmacological Action
- Radiopharmaceuticals
- Fluorodeoxyglucose F18
Other Study ID Numbers
- 2014-A01614-43
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pseudoxanthoma Elasticum
-
Fundación Pública Andaluza para la Investigación...UnknownGrönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Spain
-
Tianjin Eye HospitalCompletedElasticum, Incomplete PseudoxanthomaChina
-
University Hospital, AngersCompletedPseudoxanthoma ElasticumFrance
-
Mark LebwohlCompletedPseudoxanthoma ElasticumUnited States
-
University Hospital, AngersUnknown
-
Daiichi Sankyo, Inc.PXE InternationalActive, not recruitingPseudoxanthoma ElasticumUnited States, Netherlands
-
Daiichi Sankyo, Inc.Thomas Jefferson University; PXE InternationalCompletedPseudoxanthoma ElasticumUnited States
-
Tampere University HospitalUMC Utrecht; Hungarian Academy of SciencesWithdrawnPseudoxanthoma Elasticum
-
University Hospital, BonnUnknown
-
University Hospital, AngersCompletedPseudoxanthoma Elasticum | EmploymentFrance
Clinical Trials on PET scan 18-FDG and 18-NAF
-
University of California, Los AngelesCenters for Medicare and Medicaid ServicesCompleted
-
Case Comprehensive Cancer CenterWithdrawnMalignant Neoplasm of ProstateUnited States
-
National Cancer Institute (NCI)CompletedMultiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple MyelomaUnited States
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruitingThyroid Cancer | Lymph Node Metastases | Positron-Emission TomographyChina
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate CancerUnited States
-
Ottawa Heart Institute Research CorporationTerminatedPulmonary HypertensionCanada
-
University of Alabama at BirminghamRecruitingIdiopathic Pulmonary FibrosisUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingLiver MetastasesUnited States
-
National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Siemens Molecular ImagingTerminatedCarotid StenosisUnited States